A study from the University of Chicago reveals that zeaxanthin, a carotenoid typically associated with eye health, may play a significant role in enhancing cancer immunotherapy. The research, published in *Cell Reports Medicine*, indicates that zeaxanthin boosts the activity of CD8+ T cells, which are vital for identifying and destroying cancer cells. By stabilizing the T-cell receptor complex, zeaxanthin enhances T-cell activation and cytokine production, leading to improved tumor-killing capabilities. In mouse studies, dietary zeaxanthin slowed tumor growth, especially when combined with immune checkpoint inhibitors, a recent advancement in cancer treatment. Laboratory tests on human T cells engineered to target specific cancer markers showed that zeaxanthin increased their effectiveness against melanoma, multiple myeloma, and glioblastoma. Given its accessibility and low cost, zeaxanthin could quickly be tested as a complementary cancer treatment. However, researchers emphasize the need for clinical trials to validate these findings and explore the potential of dietary components in cancer care.